Glucocorticoid and IVIG therapy for LIP is ineffective but rituximab at a low dose (150 mg/m2) appears to be a good therapeutic regimen because of the same effectiveness as standard dose (spleen size, FVC, remission period) and compensatory increase of innate immune response as well as T cell activation with CD38 expression. This evidence concerns the gene CD38 and oral cavity neoplasm.